~ Buy the SODIUM PHENYLACETATE AND SODIUM BENZOATE (sodium benzoate; sodium phenylacetate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SODIUM PHENYLACETATE AND SODIUM BENZOATE

All Clinical Trials for SODIUM PHENYLACETATE AND SODIUM BENZOATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004767 ↗	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	Johns Hopkins University	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	National Center for Research Resources (NCRR)	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00597909 ↗	Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy	Terminated	Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 2	2007-12-01	The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).
NCT00977600 ↗	A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)	Completed	Ucyclyd Pharma, Inc.	Phase 1	2005-03-01	To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.
NCT00977600 ↗	A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)	Completed	Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 1	2005-03-01	To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.
NCT04155567 ↗	A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants	Completed	Takeda	Phase 1	2019-11-13	The purpose of this study is to evaluate the PK, safety and tolerability of phenylacetate and benzoate after intravenous administration of TAK-123 in Japanese healthy adult male participants.

Clinical Trial Conditions for SODIUM PHENYLACETATE AND SODIUM BENZOATE

Condition Name

Condition Name for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Intervention	Trials
Amino Acid Metabolism, Inborn Errors	1
Healthy	1
Healthy Volunteers	1
Hepatic Encephalopathy	1

Condition MeSH

Condition MeSH for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Intervention	Trials
Hepatic Encephalopathy	1
Brain Diseases	1
Urea Cycle Disorders, Inborn	1
Metabolism, Inborn Errors	1

Clinical Trial Locations for SODIUM PHENYLACETATE AND SODIUM BENZOATE

Trials by Country

Trials by Country for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Location	Trials
United States	2
Japan	1
Ukraine	1

Trials by US State

Trials by US State for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Location	Trials
Texas	1
California	1

Clinical Trial Progress for SODIUM PHENYLACETATE AND SODIUM BENZOATE

Clinical Trial Phase

Clinical Trial Phase for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	2

Clinical Trial Status

Clinical Trial Status for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Clinical Trial Phase	Trials
Completed	3
Terminated	1

Clinical Trial Sponsors for SODIUM PHENYLACETATE AND SODIUM BENZOATE

Sponsor Name

Sponsor Name for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Sponsor	Trials
Horizon Pharma Ireland, Ltd., Dublin Ireland	2
Takeda	1
Johns Hopkins University	1

Sponsor Type

Sponsor Type for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Sponsor	Trials
Industry	3
Other	2
NIH	1